Browsing “Managed MarketsManaged Markets | EVERSANA”

How COVID-19 Has Changed Payer Engagement Strategies

The healthcare industry is rightly focused on COVID-19 and its impact on patient care and allocation or utilization of healthcare resources. However, we cannot lose sight of our responsibility to provide appropriate therapeutic options for the over 150 million Americans who suffer from chronic diseases, including the 25-35 million Americans who suffer from rare diseases. […]

Unlocking the Potential of Revenue Management Data – Webinar

Revenue management systems hold valuable data with tremendous potential to provide business insights. Unfortunately, the power of this data is often locked behind technology barriers and reporting roadblocks such as: Data and analytics sourced from multiple platforms Transactional data sets varying across lines of business Differing objectives across departments In this webinar, EVERSANA’s Managing Consultant, […]

Oncology Treatment Access in 2020 and Beyond

2020 promises to be eye-opening as the coming election will surely provide clarity to the path that we will be taking for oncology treatment access. From international reference pricing, acceleration of biosimilars and generics, and allowance of reimportation – pressure continues to mount to reduce pharmaceutical prices, especially those used to treat cancer. Much of […]

Rethinking Patient Centricity in a Dynamic Market Access Driven Ecosystem

Understanding the Complexities and Interdependencies that Deliver Successful Outcomes. As the industry moves to a patient-centric, value-based care model, stakeholders across the continuum of care are focused on creating systems and solutions that put the patient at the forefront of decision making. This requires an alignment of priorities, such as patient engagement, HCP practice efficiency, […]

Strategies to Ensure Market Success of a Rare Disease Product Launch

Small patient populations, complex administration, high costs of therapies, and government policy interventions are just a few obstacles in rare disease. EVERSANA’s Managing Director, Bill O’Bryon, and Senior Director, Diann Johnson, outline key insights to consider in your launch strategy: Market dynamics impacting rare disease therapies The entire rare community: patients, caregivers, providers & advocates […]

Gross-to-Net Improvement Through Holistic Revenue Enhancement

Consistent price increases have long been a staple of commercial strategy for pharmaceutical manufacturers. From this uplift in topline revenue, more sizable discounts can be provided to industry middlemen, like pharmacy benefit managers (PBMs), in order to secure more favorable formulary positioning. Rather than continue forward with traditional market access strategies, manufacturers should consider revenue […]

Federal Enforcement of Clinical Pathways Resource Utilization Management

Providers order unnecessary tests for a variety of reasons: pressure from patients, fears of malpractice suit, not being knowledgeable about current “best” practices as well as for potential financial advantage for them or their health system. Clinical pathways built on solid clinical guidelines have the potential to lower costs through reduced resource utilization of potentially, […]

Adopting a Patient-Centric Approach to Ensure Safe and Effective Use

Healthcare leaders often talk about ensuring that the right patient receives the right medication at the right time. On its face, this concept seems straightforward. We know that different patients respond differently to different therapies, such that we cannot consistently replicate randomized clinical trial experience in the real world. Thus, healthcare providers (HCPs) must make […]

Building a Service Offering from the Research Lab to the Patient’s Home

A Conversation with Pharmaceutical Commerce & Jim Lang, Chief Executive Officer, EVERSANA Not quite a year ago, an assemblage of pharma service providers came into being as EVERSANA. Funded by two private equity firms with a background in healthcare—Water Street Healthcare Partners and JLL Partners, there were six acquisitions at the time: Dohmen Life Science […]

Power in numbers: Seven national plans manage almost half of the medical lives in the U.S.

Market Access Macrotrends provides  insight for you to stay on top of market access trends, anticipate how the healthcare landscape is evolving, and provide strategic guidance for your organization. Market Access Macrotrends answers your questions about changes in the access environment related to: • Current and emerging U.S. access trends • Response by stakeholders to market access […]